Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31,780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Xu B, Sun T, Shi Y, Cui J, Yin Y, Ouyang Q, Liu Q, Zhang Q, Chen Y, Wang S, Wang X, Tong Z, Zhong Y, Wang J, Yan M, Yan X, Wang C, Feng J, Wang X, Hu G, Cheng Y, Ge R, Zhu Z, Zhang W, Shao Z. Xu B, et al. Among authors: shi y. Breast Cancer Res Treat. 2023 Feb;197(3):489-501. doi: 10.1007/s10549-022-06785-z. Epub 2022 Dec 2. Breast Cancer Res Treat. 2023. PMID: 36459284 Free PMC article. Clinical Trial.
Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C, Wei W, Sun P, Zheng W, Diao X, Xu F, Huang J, An X, Xia W, Hong R, Jiang K, Huang R, Yuan Z, Wang S, Li A, Zou R, Shi Y. Xue C, et al. Among authors: shi y. Breast Cancer Res Treat. 2019 Feb;173(3):619-628. doi: 10.1007/s10549-018-4997-2. Epub 2018 Nov 3. Breast Cancer Res Treat. 2019. PMID: 30392113
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Sheng X, et al. Among authors: shi b, shi y. Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27. Clin Cancer Res. 2021. PMID: 33109737 Clinical Trial.
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.
Xu F, Zheng Q, Xia W, Ouyang Q, Pang D, Yuan Z, Shi Y, Peng R, Lu Q, Wang S. Xu F, et al. Among authors: shi y. Oncologist. 2021 May;26(5):e742-e748. doi: 10.1002/onco.13614. Epub 2020 Dec 8. Oncologist. 2021. PMID: 33245164 Free PMC article. Clinical Trial.
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.
Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L, Zhang Q, Qiu W, Xu B, Xu R, Shen B, Luo Z, Xie X, Chang J, Wang M, Li Y, Shuang Y, Niu Z, Liu B, Zhang J, Zhang L, Yao H, Xie C, Huang H, Liao W, Chen G, Zhang X, An H, Deng Y, Gong P, Xiong J, Yao Q, An X, Chen C, Shi Y, Wang J, Wang X, Wang Z, Xing P, Yang S, Zhou C. Ba Y, et al. Among authors: shi y. Cancer Biol Med. 2020 Nov 15;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15. Cancer Biol Med. 2020. PMID: 33299642 Free PMC article. Review.
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study.
Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, Li S, Yu J, Wei J, Tang W, Zhou D, An X, Huang J, Xue C, Bi X, Shi Y, Yuan Z, Xu F, Wang S. Hong R, et al. Among authors: shi y. Cancer Commun (Lond). 2021 Feb;41(2):171-182. doi: 10.1002/cac2.12135. Epub 2021 Feb 2. Cancer Commun (Lond). 2021. PMID: 33528890 Free PMC article. Clinical Trial.
31,780 results
You have reached the last available page of results. Please see the User Guide for more information.